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Mast cells are localized in tissues. Intense research on these cells over the years has
demonstrated their role as effector cells in the maintenance of tissue integrity follow-
ing injury produced by infectious agents, toxins, metabolic states, etc. After stimulation
they release a sophisticated array of inﬂammatory mediators, cytokines, and growth fac-
tors to orchestrate an inﬂammatory response. These mediators can directly initiate tissue
responses on resident cells, but they have also been shown to regulate other inﬁltrating
immune cell functions. Research in recent years has revealed that the outcome of mast
cell actions is not always detrimental for the host but can also limit disease development.
In addition, mast cell functions highly depend on the physiological context in the organ-
ism. Depending on the genetic background, strength of the injurious event, the particular
microenvironment, mast cells direct responses ranging from pro- to anti-inﬂammatory. It
appears that they have evolved as cellular sensors to discern their environment in order to
initiate an appropriate physiological response either aimed to favor inﬂammation for repair
or at the contrary limit the inﬂammatory process to prevent further damage. Like every
sophisticated machinery, its dysregulation leads to pathology. Given the broad distribution
of mast cells in tissues this also explains their implication in many inﬂammatory diseases.
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INTRODUCTION
Mast cells are tissue-localized cells of hematopoietic origin. They
have originally been named by Paul Ehrlich as “Mastzellen,”which
in German stands for well-fed cells. He thought that their numer-
ous cytoplasmic granules visualized after metachromatic staining
with aniline dyes, were a feature of intense ingestion of nutrients
by phagocytes (Ehrlich, 1878). Riley and West (1953) published
that mast cell numbers in tissues are correlated with the tissue
histamine content and that exceptional high amounts are found
in dog mastocytomas. Histamine had been described somewhat
earlier by Dale and Laidlaw (1910) to mediate the anaphylactic
shock deﬁned by Portier and Richet (1902) as an unusual reaction
of dogs to the injection of toxins isolated from the sea anemone
Physalia. These landmark studies established mast cells as impor-
tant inﬂammatory effectors, a concept that has largely evolved ever
since, with mast cells being now well-recognized effector cells in
immunity and inﬂammatory responses.
Since then, mast cells have been found to be largely distributed
throughout virtually every tissue of the body where upon stim-
ulation they produce a whole set of biologically active products.
This enables them to mediate tissue responses, fulﬁll immunoreg-
ulatory functions, participate in the attraction of other immune
effector cells or organize tissue remodeling (Marshall, 2004; Galli
et al., 2005, 2008a; Bischoff, 2007; Abraham and St John, 2010).
As mast cells express high afﬁnity IgE receptors (FcεRI) that inter-
act with IgE antibodies, research on these cells has initially been
driven by their implication in IgE-mediated type I immediate
hypersensitivity reactions and allergic diseases (Metcalfe et al.,
1997; Beaven, 2009; Hakim-Rad et al., 2009), the focus has now
evolved extending to the study of their role in different physiolog-
ical and pathophysiological settings (Maurer et al., 2003; Marshall,
2004; Galli et al., 2005, 2008a; Bischoff, 2007; Abraham and St
John, 2010). This was at least in part made possible by the avail-
ability of mast cell-deﬁcient animal models (Galli et al., 2005;
Grimbaldeston et al., 2005). The accumulated evidence obtained
so far show that mast cells are an integral part of the immuno-
logical surveillance system that act together with other immune
cells to mount speciﬁc reactions in response to an inﬂammatory
insult. Most importantly, while they have been considered initially
as inﬂammatory effector cells whosemain rolewas to contribute to
pathologies such as allergies,many mast cell physiologic functions
have now been unveiled (Marshall, 2004; Galli et al., 2005, 2008a;
Bischoff, 2007; Abraham and St John, 2010). These studies have
made clear that physiology and pathology are often closely delim-
ited and that small differences in mast cell environment yields
variant and even opposite functions. In the following review we
present some of the recent advances made in our understanding
of mast cell functions with a particular emphasis on the multiple
faces and spectrum of responses these cells can deliver following
inﬂammatory signals.
FUNDAMENTAL NOTIONS ABOUT MAST CELLS
Mast cells originate from a common precursor in the bone mar-
row. They are poorly characterized in the blood as they rapidly
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enter tissues under the inﬂuence of various growth factors to com-
plete their ﬁnal differentiation (Metcalfe et al., 1997; Hallgren and
Gurish, 2007). The major growth factor is c-kit-binding stem cell
factor (SCF). However, other factors including IL-3, IL-4, IL-9,
NGF, and TGFβ1 also support to various degrees mast cell growth
and differentiation (Kitamura, 1989; Galli et al., 2005; Ryan et al.,
2007). Depending on the particular tissue, mast cells further dif-
ferentiate into subpopulations, which led to the concept of mast
cell heterogeneity. Tentatively, two types of mast cell populations
have been distinguished including connective tissue-type mast
cells and mucosal mast cells in rodents or tryptase/chymase and
tryptase positive mast cells in humans (Enerback, 1966; Metcalfe
et al., 1997; Beaven, 2009; Tsuboi et al., 2011). Additional speciﬁc
features can be acquired depending on the microenvironment in
tissues. The phenotypic heterogeneity also translates into a func-
tional heterogeneity governed for example by the expression of
various sets of receptors (Metcalfe et al., 1997; Beaven, 2009). Mast
cells are preponderant in all tissues lining outer surfaces such as
the skin, the airways, or the gut. Often, they can be found closely
associated to blood vessels and nerve endings. However, mast cells
exist in noticeable quantities in virtually every tissue. Even in tis-
sues sparsely populated with mast cells, their number can increase
markedly under inﬂammatory conditions i.e., in kidneys during
the development of chronic kidney diseases (CKD; Blank et al.,
2007). Mast cells express a large set of receptors on the cell surface
or intracellularly allowing them to respond to a large variety of
stimuli in tissues. The best studied mechanism of activation is the
aggregation of the high afﬁnity IgE receptor (FcεRI) implicated
in allergic reactions. However, numerous other activation mecha-
nisms have been characterized including, for instance, stimulation
through innate immune receptors such as TLRs or complement
receptors, or receptors for inﬂammatory peptides, hormones, and
other compounds. Interestingly, while IgE receptor stimulation
usually launches a complete program of stimulation with release
of inﬂammatory products from cytoplasmic granules followed by
the release of newly synthesized products, some stimuli, like TLR-
ligands, CD30 ligand or vitamin D, selectively activate mast cells to
release particular sets of cytokines (Marshall, 2004; Fischer et al.,
2006; Galli et al., 2008a; Beaven, 2009; Biggs et al., 2010). Some of
these stimuli also have a priming function to increase the secre-
tory response or alter the response proﬁle to a subsequent stimulus
(Fifadara et al., 2009; Andrade et al., 2011). Mast cells store many
of their inﬂammatory products, like histamine, proteoglycans or
speciﬁc proteases, in cytoplasmic granules, where they are ready
for immediate release within a fewminutes. Others, such as arachi-
donic acid metabolites or chemokines/cytokines are newly synthe-
sized and in consequence are released somewhat later in the range
of 10min up to several hours or even days. Some cytokines such as
TNF can also be found in cytoplasmic granules where they can be
released immediately. In additionnew types of responses havebeen
discovered recently such as the formation of extracellular nets, pre-
viously described in neutrophils (Brinkmann et al., 2004). These
are composed of DNA, histones, tryptase, and the antimicrobial
peptide LL-37, with growth inhibitory effects for Streptococcus
pyogenes (Von Kockritz-Blickwede et al., 2008), Furthermore, syn-
ergistic cross-talk between FcεRI and chemokine receptors was
shown topromote F-actin-rich cytoneme extensions betweenmast
cells that may play a role in intercellular communication (Fifadara
et al., 2010).
Research on the role of mast cells in health and disease has
largely beneﬁted from the availability of several mast cell-deﬁcient
animalmodels, themost utilized being theW/Wv mouse andmore
recently the Wsh/Wsh mouse (Galli et al., 2005; Grimbaldeston
et al., 2005). Both carry natural, albeit different, mutations in the
c-kit gene, a major growth factor receptor involved in mast cell
differentiation. These strains of mice have been used in various
physiological settings and experimental disease models to probe
for the role of mast cells. Although these mice are profoundly
deﬁcient in mast cells as compared to wild-type mice, they carry
other deﬁciencies that differ somewhat between the two strains
(Nocka et al., 1990; Grimbaldeston et al., 2005; Zhou et al., 2007;
Nigrovic et al.,2008;Mancardi et al.,2011; seeTable 1). In addition,
described deﬁciencies do not always coincide between studies car-
ried out by various investigators, which may at least in part be due
to colony conditions or the age of mice at time of investigations.
Therefore, to effectively evaluate whether these cells are essential
or contribute to an observed biological effect, it is always necessary
to selectively reconstitute these mice with mast cells.Without such
engraftment studies, sometimes important differences in exper-
imental results obtained with these strains that could be related
to the accompanying abnormalities might be misinterpreted as
mast cell-dependent. For example, due to the relative neutrophilia
observed inWsh mice,mast cell dependent effects could bemasked
in case of an important contribution of neutrophils in pathologi-
cal conditions, whereas this is less the case in W/Wv mice, which
have neutropenia. This indicates that mast cells do not act alone
but that they highly depend on their interaction with other com-
ponents of their physiopathological environment. It should be
noted that engraftment with mast cells does not exactly repro-
duce the distribution found in wild-type mice and reconstitution
times largely differ between various tissues (Tanzola et al., 2003).
Therefore, in addition to these classically used mouse models new
transgenic mast cell-speciﬁc Cre mice have been under develop-
ment (Musch et al., 2008; Scholten et al., 2008) where Cre is under
control of the Mcpt5 and baboon a-chymase promoter, respec-
tively. However, their complete characterization is still in progress.
In addition, several mouse models that lack mediators or recep-
tors that are relatively mast cell speciﬁc have been used to test the
impact of deﬁciency in various experimental set-ups and disease
models. They include for example mice lacking high afﬁnity IgE
receptor alpha or beta chains as well as mice deﬁcient in various
proteases such as mast cell protease 1 (MCP-1), MCP-4, MCPT6
(β2-tryptase), or carboxypeptidase A3 (CPA3; Knight et al., 2000;
Tchougounova et al., 2004; Abonia et al., 2005; McNeil et al., 2008;
Hamilton et al., 2011).
MAST CELLS AS ACTORS OF IMMEDIATE
HYPERSENSITIVITY REACTIONS IN TISSUES
For a long time, mast cells together with basophils have been
recognized as effectors of the classically deﬁned IgE-mediated
immediate type I hypersensitivity response characterized by the
massive release of inﬂammatorymediators bydegranulation (Met-
calfe et al., 1997; Bradding, 2003; Blank and Rivera, 2004; Galli
et al., 2008b). Similar types of responses can be triggered by
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Table 1 | Comparison of phenotypic abnormalities in mast cell-deficient C57BL/6–KitWsh/W-sh andWBB6F1–KitW/W-v mice as compared to
wild-type animals.
Phenotypic abnormalities of
naive mice
C57BL/6–KitWsh/W-sh WBB6F1–KitW/W-v References
Mutation in c-kit Gene inversion: disrupts
c-kit promoter region and
corin (cardiac protease)
W: c-kit null allel, Wv:
point mutation in c-kit
kinase domain
Nocka et al. (1990), Grimbalde-
ston et al. (2005), Nigrovic et al.
(2008)
Anemic No Yes Grimbaldeston et al. (2005)
Sterile No Yes Grimbaldeston et al. (2005)
Mixed background No Yes Grimbaldeston et al. (2005)
Partially deaf No Yes Grimbaldeston et al. (2005)
Prone to dermatitis and gastritis Grimbaldeston et al. (2005)
Prone to stomach papillomas and gastritis No Yes Grimbaldeston et al. (2005)
Enlarged and histologically abnormal spleen Yes (in old mice) No Nigrovic et al. (2008)
Alteration of γδT cell numbers in small intestine No Yes Grimbaldeston et al. (2005)
Develop idiopathic dermatitis No Yes Grimbaldeston et al. (2005)
Blood neutrophils Increased Decreased Nigrovic et al. (2008), Zhou et al.
(2007), Mancardi et al. (2011)
Neutrophils (GR-1) in bone marrow Increased Decreased Nigrovic et al. (2008)
Neutrophils (GR-1) in spleen Increased Decreased Nigrovic et al. (2008)
Platelets Increased Normal Nigrovic et al. (2008)
Blood basophils Increased Decreased Mancardi et al. (2011)
Basophils in spleen Normal Normal Grimbaldeston et al. (2005)
Basophils in bone marrow Normal Normal Grimbaldeston et al. (2005)
B cells in bone marrow and spleen Normal Normal Grimbaldeston et al. (2005)
T cells (CD4, CD8) in thymus and spleen Normal Normal Grimbaldeston et al. (2005)
Monocytes/macrophages (F4/80) in bone marrow Decreased Increased Nigrovic et al. (2008)
Monocytes/macrophages (F4/80) in spleen Increased Normal Nigrovic et al. (2008)
Megacaryocytes in spleen Increased ND Nigrovic et al. (2008)
Develop mast cells after engraftment with bone
marrow cells
No Yes Grimbaldeston et al. (2005)
Markedly reduced c-kit signaling Yes Yes Grimbaldeston et al. (2005)
Lack of mast cells in all tissues of adult mice Yes Yes Grimbaldeston et al. (2005)
Lack of interstitial cells of Cajal Yes Yes Grimbaldeston et al. (2005)
Develop mast cells after engraftment with bone
marrow derived mast cells
Yes Yes Grimbaldeston et al. (2005)
Exhibit bile reﬂux Yes Yes Grimbaldeston et al. (2005)
Lack melanocytes Yes Yes Grimbaldeston et al. (2005)
various other agents and tissue factors including complement
fragments, inﬂammatory products, and neuropeptides (Table 2;
Maurer et al., 2003; Theoharides et al., 2010). This reactivity con-
tributes importantly to the immunosurveillance function of these
cells ready to respond instantly to tissue injury of traumatic, toxic,
auto-immune or infectious origin. It appears that immunologi-
cal alteration through the production of immunoglobulin E (IgE)
antibodies to normally harmless substances has somehowhijacked
this type of inﬂammatory response of mast cells to cause allergic
disease. Indeed, together with blood basophils, mast cells express
high afﬁnity IgE receptors (FcεRI; Mendoza and Metzger, 1976),
IgE being identiﬁed a few years earlier as the serum factor respon-
sible for anaphylaxis, allergies, and asthma (Frick and Ishizaka,
1970; Lichtenstein et al., 1970). The study of their implications
and the mechanisms of pathophysiology in IgE-mediated type I
immediate type hypersensitivity has for a long time predominated
in the mast cell research ﬁeld. Besides leading to the characteriza-
tion of the molecular structure of this receptor (Blank et al., 1989;
Miller et al., 1989) and its signaling pathways (Kinet, 1999; Met-
calfe et al., 2009; Benhamou and Blank, 2010), they also revealed
that besides histamine and other granule-stored mediators, mast
cells can produce a large set of inﬂammatory mediators includ-
ing prostaglandins, leukotrienes, and many different chemokines,
cytokines, and growth factors (Gurish andAusten,2001;Galli et al.,
2008a; Beaven, 2009). This attributed a role to mast cells also in
the late phase allergic reactions including chronic inﬂammatory
and remodeling responses during development of asthma. How-
ever, these studies did not resolve the enigmatic question raised
at the turn of the twentieth century by Paul Portier and Charles
Richet on the role of anaphylaxis in immunity as this contradicted
immunity’s protective function (Portier andRichet, 1902). Indeed,
it was difﬁcult to conceive that the unique goal of the IgE/mast cells
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Table 2 | Some of the receptors (R) expressed by mast cells.
Receptors Ligands Mast cell responses References
ADAPTIVE IMMUNITY
FcεRI IgE/(+ antigen) Preformed mediators, neoformed mediators
(lipid-derived; cytokines/chemokines)
Kinet (1999), Bryce et al. (2004)
huFcγRIIA huFcγRI
(IFNγinduced) moFcγRIIIA
IgG/antigen IC Preformed mediators, neoformed mediators
(lipid-derived; cytokines/chemokines)
Malbec and Daeron (2007)
IgG/antigen
IgG/antigen IC
moFcγRIIB IgG/antigen, co-crosslinking with
moFcγRIIIA or moFcεR1
Inhibition of pre- and neoformed mediator
release
Malbec and Daeron (2007)
MHC I Antigenic peptides Antigen-speciﬁc T cell responses Stelekati et al. (2009), Valitutti and
Espinosa (2010)
MHC II Antigenic peptides Antigen-speciﬁc T cell responses Frandji et al. (1996), Valitutti and
Espinosa (2010)
INNATE IMMUNITY
C3a receptor C3a Pre- and neoformed mediators Ali (2010)
C5a receptor C5a Pre- and neoformed mediators Ali (2010)
TLR1-9 Bacterial products: PAMPS
Virus: Ds DNA Ss RNA
Neoformed mediators Marshall (2004), Abraham and St
John (2010)
CD48 (H) E. coli Fim H, M. tuberculosis
antigen
Pre- and neoformed mediators Marshall (2004), Abraham and St
John (2010)
ENDO/EXOGENOUS PEPTIDE R
ETA; ETB Endothelin-1 Preformed mediators Maurer et al. (2004)
Neurokinin receptor Substance P Pre- and neoformed mediators Metz and Maurer (2007)
GPCR mimetic MRGX2? Mastoparan (peptide from wasp
venom), polybasic compounds
Preformed and neoformed mediators Theoharides et al. (2010)
Hormone R
Progesterone R Progesterone Regulation of mast cell migration, regulation
of receptor expression, preformed mediator
release
Theoharides et al. (2010), Jensen
(2000)
Estradiol receptor Estradiol Regulation of mast cell migration, regulation
of receptor expression, preformed mediator
release
Theoharides et al. (2010), Jensen
(2000)
Corticotropin-
corticotropin-releasing
hormone R
CRH, urocortin Pre- and neoformed mediator release Theoharides et al. (2010), Jensen
(2000)
CHEMOKINE R
Chemokine receptors
CXCR1–4, CX3CR1 CCR1,
3–5
Chemokines Migration of mast cells, enhancement of
pre-and neoformed mediator secretion,
scytonema formation
Marshall (2004), Fifadara et al.
(2009)
OTHER R
VDR Vitamin D Neoformed mediator secretion (IL-10) Biggs et al. (2010)
axis is to cause hay fever, food allergies, urticaria, asthma, etc. At
least under some circumstances and particularly during parasite
infections, evidence has nowaccumulated that IgE-mediated effec-
tor mechanisms of mast cells participate in host protection (see
below).
Furthermore, recent works nicely offer some new clues about
how hypersensitivity reactions participate in host protection.
Endothelin-1 (ET-1), a 21 aa inﬂammatory and potent vasocon-
strictor peptide released by endothelial cells, is implicated in a
wide spectrum of pathological processes including sepsis, asthma,
peripheral, acute, and chronic renal failure, cutaneous disorders,
etc. (Maurer et al., 2004). Work by Marcus Maurer in the labora-
tory of Stephen Galli elegantly showed that ET-1 can be rapidly
inactivated by mast cell-released carboxypeptidaseA (CPA), a pro-
tease stored in cytoplasmic granules. ET-1 itself can activate mast
cells to release CPA suggesting a negative feed-back loop of regula-
tion. The high homology of this peptidewith sarafotoxins, a potent
venom component of the Israeli mole viper led to another intrigu-
ing set of data revealing the protective action of mast cell granule
components.Metz et al. (2006) in the same laboratory showed that
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released CPA was responsible for diminished circulating levels of
sarafotoxin. Following injection, the latter remained highly ele-
vated in mast cell-deﬁcient mice,mice treated with CPA inhibitors
or mast cell-deﬁcient mice reconstituted with CPA-deﬁcient mast
cells. This protective function was also conﬁrmed against a variety
of other snake venoms. Most strikingly, while honeybee venom
can lead to severe IgE-mediated anaphylactic shock responses in
susceptible IgE-sensitized patients, the authors provided evidence
that injection of honeybee venom, which contains many mast cell
degranulating agents, causes mortality with extensive hematuria
in mast cell-deﬁcient mice. More recently, mast cells were also
shown to reduce neurotensin peptide levels, which contributes
to protect against sepsis-related mortality in mice in the cecum
ligation and puncture (CLP) model. Again this involved mast
cell released proteases in particular neurolysin and to a minor
extent CPA (Piliponsky et al., 2008). Taken together, these studies
clearly sustain that mast cells have evolved as specialized effec-
tors that via immediate type hypersensitivity-like reactions and
ensuing release of inﬂammatory products such as proteases stored
in mast cell granules play an important role in venom detoxi-
ﬁcation (Figure 1). The other side of the coin is that this type
of reaction can also endanger certain individuals notably those
exhibiting exaggerated IgE-mediated hypersensitivity reactions to
honey bee venoms. They also endanger individuals developing
immune responses to “harmless” environmental antigens (aller-
gens; Galli et al., 2008b),which could be the result of the increasing
inadequacy of the immunological adaption to a rapidly changing
modern hygienic society (Bach, 2002).
MAST CELLS AND ADAPTIVE IMMUNITY
Mast cells have the capacity to directly participate in adaptive
immunity via the expression of Fc receptors that function as
signaling modules that relay the antigen binding speciﬁcity of
immunoglobulin ligands. This type of activation may contribute
to pathology, in particular autoimmunity. Besides the high afﬁnity
IgE receptor (FcεRI), mast cells also express receptors for IgG sub-
classes conferring mast cells responsiveness to stimulation with
IgG immune complexes. Mouse mast cells express the activat-
ing FcγRIIIA, human MCs express both the activating FcγRIIA
and under certain conditions FcγRI, the latter being induced
by low concentrations of IFNγ. Mouse mast cells also express
FcγRIIB, while its expression in human MCs is not ﬁrmly estab-
lished (Malbec and Daeron, 2007). FcγRIIB functions as a general
inhibitor of cell activation when co-aggregated with another acti-
vating immune receptor. Mast cells promote adaptive immunity
also by their ability to present antigen through MHC class I and II
molecules (Frandji et al., 1996; Stelekati et al., 2009; Valitutti and
Espinosa, 2010). They also may participate indirectly by releas-
ing immunoregulatory cytokines or by their ability to recruit and
regulate other cells of the adaptive immune system as shown for
example for T lymphocytes, regulatory T lymphocytes or B lym-
phocytes (Ott et al., 2003; Lu et al., 2006; Merluzzi et al., 2010; see
also below) and by their ability to function as adjuvants for the
elaboration of immune responses (McLachlan et al., 2008).
Early studies published in the 1960s (Ogilvie, 1964) showed
that “reagin-like” IgE antibodies were elevated during helminth
infections, giving some hints of the participation of IgE-mediated
FIGURE 1 | Immediate hypersensitivity responses to inactivate endo-
or exogenous venoms.While IgE-dependent hypersensitivity reactions
have been known for long to initiate allergic responses, recent research has
unveiled that this type of response can also be activated by certain
endogenous or exogenous toxins, which cause the mast cells to release
granule-stored proteases, which in a feed-back mechanism can inactivate
these toxins through proteolytic cleavage. Thus endogenously produced
highly active pharmacological peptides such as endothelin-1 and
neurotensin can be cleaved with mast cell-released carboxypeptidase A and
neurolysin, respectively. Similarly certain snake venoms such as
sarafotoxins, which bear homology to endothelin-1 can also be cleaved by
CPA. Interestingly, while honeybee venom has been shown in some cases
to cause IgE-dependent deadly anaphylactic reactions, mast cell released
products also serve to inactivate this venom and limit its toxicity.
effector mechanisms in the defense against parasites. Many other
studies conﬁrmed the marked elevation of IgE levels in an envi-
ronment with endemic helminth parasite infections and the sites
of infection have often been associated with an important recruit-
ment and/or the proliferation of IgE-receptor-bearing mast cells
(Lynch et al., 1984; Bell, 1996). Although, this could be secondary
to the parasite-induced promotion of TH2 responses character-
ized by several other features (IL-4, IL-5, IL-13, eosinophilia,
basophilia, etc.), at least in some cases both IgE and mast cells
contribute to antiparasitic defense mechanisms (Finkelman and
Urban, 2001; Anthony et al., 2007). Thus, transfer of IgE from
Trichinella spiralis-infected animals conferred resistance to naïve
animals (Ahmad et al., 1991). Studies conducted with IgE- and
mast cell-deﬁcient mice showed that both mast cells and IgE can
actively participate to the resistance to various nematodes (Abe
and Nawa, 1987; Lantz et al., 1998), ticks (Haemaphysalis longicor-
nis; Matsuda et al., 1990), and protozoans (Li et al., 2004). Some
of their actions rely on proteases such as the mast cell tryptase
mMCP-6 (Shin et al., 2008) and mucosal mast cell chymase
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mMCP-1 (Knight et al., 2000). However, results on this host
protective function were variable and largely depended on the
parasite species under study leading in some cases to conclude
to an absence of a mast cell role or even to a disease-promoting
function, such as the case for the tick Dermacentor variabilis (Den-
hollander and Allen, 1985; Anthony et al., 2007). Furthermore,
while in some cases mast cells showed efﬁciency during primary
IgE-independent infection, other studies showed that they were
efﬁcient only during secondary infections, i.e., adaptive immu-
nity (Finkelman and Urban, 2001). A striking example of the
complexity of the response proﬁle was provided recently in the
model of tick infection with H. longicornis using both mast cell
and basophil-deﬁcient mice (Wada et al., 2010). The authors con-
ﬁrmed the role of mast cells in secondary infection, but showed at
the same time that basophils were also necessary to confer resis-
tance to secondary infection and likely are the effectors of the IgE
and/or FcR-mediated response. While resistance was ablated in
FcRγ-deﬁcientmice devoid of any activating FcR (FcεRI, FcγRIII),
mice reconstituted with FcRγ-deﬁcient mast cells were still able to
restore protection after engraftment supporting a role of basophils
in FcγR-mediated effects and concomitant cooperation with mast
cells in the mechanisms leading to host resistance. They also show
that adaptive IgE-mediated effector mechanisms do not necessar-
ily need to involve mast cells, but could rely also on basophils.
These studies make clear that it is the combined action of various
TH2-dependent effector mechanisms that contribute to host pro-
tection during parasite infection. Such effector mechanisms may
involve direct killing by tissue-localized and/or recruited effector
cells through released mediators (proteases, enzymes, ROS, etc.),
enhanced mucus production with entrapment of parasites (weep
and sweep mechanism) promoted by various inﬂammatory medi-
ators including TH2 cytokines, the activation of smooth muscle
contraction promoting expulsion as well as the coordination of
an efﬁcient inﬂammatory cell cross-talk (Anthony et al., 2007). In
addition to antigen-triggered protective functions the interaction
of mast cells with IgEmay also support antigen-independent func-
tions since IgE alone can enhancemast cell survival andprimemast
cells to respond more efﬁciently during certain types of cutaneous
hypersensitivity responses (Asai et al., 2001;Kalesnikoff et al., 2001;
Bryce et al., 2004).
Although mast cells can clearly be triggered through IgG recep-
tors in vitro, few studies have examined IgG-mediated mast cell
responses. In the 1950s Zoltan Ovary established that IgG and
antigen trigger passive cutaneous anaphylaxis reactions (Ovary,
1958), that were reconsidered as mast cell-mediated Arthus reac-
tions mediated through FcγR many years later (Hazenbos et al.,
1996; Sylvestre and Ravetch, 1996). Results obtained in FcεRI-
or mast cell-deﬁcient mice established IgE-dependent stimulation
of mast cells as major effector mechanism in a passive systemic
anaphylaxis model with the effect being largely mediated by his-
tamine release (Dombrowicz et al., 1993; Miyajima et al., 1997;
Makabe-Kobayashi et al., 2002), although IgG immune com-
plexes were also shown to induce such reactions. However, in
the latter case, basophils, and more recently neutrophils acti-
vated through either FcγRIII or FcγRIV were reported to be the
relevant effector cells and the effect was mediated by Platelet-
Activating Factor (Tsujimura et al., 2008; Jonsson et al., 2011).
It is possible that, after systemic injection, the high concentra-
tion of IgG immune complexes required to stimulate mast cells
are unable to reach tissues (such as the skin) where mast cells
are localized and, therefore, activate circulating cells instead. This
may be less the case with the IgE system, as minute amounts
of speciﬁc IgE are sufﬁcient to sensitize mast cells through their
steady binding to high afﬁnity IgE receptors. Thereafter, minute
amounts of antigen alone, even intravenously injected, will be
able to reach mast cells and activate them preferentially in this
context.
In other cases, even after injection into the skin of newborn
mice of large amounts of antibodies directed against desmoso-
mal proteins to induce experimental bullous pemphigoid auto-
immune disease, mast cell degranulation did not involve FcR
stimulation but rather was triggered by complement fragments
(Chen et al., 2001). Nevertheless, recently the possible implication
of FcγRIII in the protective effects of mast cells in certain types of
cutaneous hypersensitivity responses was discussed (Grimbalde-
ston et al., 2007). Furthermore, several other studies support a
role of mast cell FcγR in pathology, notably in IgG-mediated
autoimmunity. Therefore, it is possible that at least under some
circumstances, IgG immune complexes may be involved in trig-
gering mast cell responses. Examples of experimentally induced
auto-immune diseases with implication of FcγR include EAE
(Secor et al., 2000; Sayed et al., 2011) and rheumatoid arthritis
(RA; Lee et al., 2002). In these models, which depend either on
the injection of pathologic IgG (RA) or on the development of
pathologic IgG (EAE), W/Wv mice are less susceptible to disease
and their reconstitution with WT, but not with FcRγ-deﬁcient
mast cells, restores disease susceptibility. However, again the pic-
ture is complex as, for example, the increased susceptibility to
RA was apparent in W/Wv, but not Wsh/Wsh mast cell-deﬁcient
mice. This holds true also for both the passive K/BxN (Tsuboi
et al., 2011) or active collagen-induced arthritis model (Zhou
et al., 2007) pointing out that the physiological context in each
animal model is important. In agreement, as W/Wv mice show
neutropenia (seeTable 1), reconstitutionwithneutrophils restored
susceptibility to RA in these mice (Tsuboi et al., 2011). In addition,
the K/BxN model also involved FcγRIV, a receptor not expressed
by mouse mast cells (Mancardi et al., 2011). Similarly in the EAE
model, disease susceptibility could not be shown in Wsh/Wsh
mice and discordances exist even in W/Wv mice regarding the
implication of mast cells (Bennett et al., 2009; Sayed et al., 2011)
indicating additional factors in colonies that may inﬂuence disease
initiation.
Taken together, these data reveal a complex picture of the role
of mast cells in adaptive immune defense mechanisms but also
autoimmunity. There is no doubt that IgE-dependentmechanisms
play a major role in allergies but some studies also agree on a
prime role of mast cells in IgE-dependent protection to parasitic
infections. Furthermore, new data concerning the contribution of
FcγR are emerging. The simultaneous engagement of FcεRI and
inhibitory FcγRIIB may lead to inhibition of responses although
a convincing in vivo demonstration remains to be established as
well as its signiﬁcance in human mast cells (Daeron et al., 1995).
It also has become clear that such mast cell mediated actions are
highly dependent on the endogenous environment and that mast
Frontiers in Immunology | Molecular Innate Immunity September 2011 | Volume 2 | Article 37 | 6
Beghdadi et al. Mast cell sensors
cells are rather an integral part of the effector response attributing
an important role to cross-talk with other cells to organize efﬁcient
adaptive defense mechanisms.
MAST CELLS AND INNATE IMMUNITY
Although, there is no doubt today that the adaptive and innate
immune systems are highly intertwined, it has become clear that
mast cells are highly efﬁcient effectors of primary innate immunity
against infectious agents (Marshall, 2004; Abraham and St John,
2010). While, as shown above, adaptive immunity clearly plays a
role in the defense mechanisms against parasites, the rapid action
of mast cells response during primary infection speaks for their
important role as actors of innate immunity. Emerging data show
that parasites express a variety of surfacemolecules or secrete prod-
ucts that may be able to activate mast cells, although these have
not been studied in detail so far (Robinson et al., 2010).
Following the studies by Echtenacher et al. (1996) and Malaviya
et al. (1996) showing a protective action of mast cells in an acute
model of sepsis induced by CLP,many other studies have followed
demonstrating a protective function of mast cells in bacterial
infection (Abraham and St John, 2010). These include bacterial
infections in various compartments of the human body including
peritoneum, skin bladder, airways, and lung, clearly implicating
mast cells as highly relevant cells in the body internal surveillance
system. Several types of innate immune receptors have been impli-
cated in these anti-bacterial defense mechanisms. They include
TLRs (TLR 2, TLR4, and TLR9) recognizing pathogen associ-
ated molecular patterns, CD48 recognizing E. coli FimH and
complement fragments C3a and C5a or complement receptors
CD21/CD35 and CD19 responding to byproducts of the comple-
ment cascade (Marshall, 2004; Abraham and St John, 2010; Ali,
2010).
Although multiple studies support mast cell participation in
bacterial host defense, recent data reveal again a more complex
picture indicating that mast cell-mediated actions depend on
the pathophysiological context (Piliponsky et al., 2010). Thus, in
the experimental model of sepsis induced by CLP, the mast cell
mediated protective function highly depends on the severity of
bacterial infection. In moderate sepsis induced by CLP (1/2 liga-
tion, 22 gage needle) mast cells clearly mediated protection both
in reconstituted W/Wv and Wsh/Wsh mice. In the latter, the effect
was TNFα-independent, as reconstitution of Wsh/Wsh mice with
either WT or TNF-deﬁcient mast cells was equally effective in
restoring protection. The mast cell mediated protection was not
apparent in severe CLP (2/3 ligation, 22 gage needle). Although,
mast cell-deﬁcient W/Wv were more susceptible, protection could
not be restored by engraftment of mast cells suggesting the par-
ticipation of additional c-kit-dependent effects. Surprisingly, it
seems that in the severe sepsis model,mast cell-deﬁcient Wsh mice
were less susceptible than WT mice. The enhanced pathology
could be attributed to mast cell derived TNF, as in this back-
ground engraftment with WT mast cells but not TNF-deﬁcient
mast cells restored disease susceptibility. Thus, while under cer-
tain circumstances TNF will protect the host, by contributing to
the recruitment of other immune effector cells with protective
function such as neutrophils, under circumstances of excessive
production it may also contribute to sustain a disease-aggravating
inﬂammatory response. A similar deleterious effect of mast cell-
derived TNF was also seen after intraperitoneal inoculation of
Salmonella typhimurium. Thus, like in adaptive immunity, innate
immune functions of mast cells contribute to protection or aggra-
vation of disease depending on many additional factors that
include strain background, the nature of the mutation result-
ing in mast cell deﬁciency as well as the type and severity of
infection.
Mast cells may also participate in anti-viral defense mecha-
nisms. For example, they express TLR3, a receptor recognizing
double-stranded RNA (dsRNA), a molecular pattern associated
with viral infections (Kulka et al., 2004). Such interaction induces
release of various cytokines including IFN-α and IFN-β, which
are implicated in the induction of anti-viral defense mecha-
nisms.Upon interactionwith dsRNAor reovirus infection,human
mast cells produce a variety of chemokines (CCL4, CXCL8, and
CXCL10; Burke et al., 2008). CXCL8 released by low levels of
reovirus infection induces substantial anti-viral human NK cell
chemotaxis (Burke et al., 2008). In mouse mast cells, TLR3 lig-
ands or Newcastle disease virus induced anti-viral IFN-β and
chemokine release and induced the recruitment of cytotoxic T cells
(Orinska et al., 2005). Thus, mast cells could represent an impor-
tant effector arm in the defense against viruses. However further
in vivo studies are necessary to conﬁrm such an implication. Mast
cells, may be together with basophils, respond also to some HIV
proteins including gp120 and Tat (Marone et al., 2001b). Gp120
interacted with the VH3 domain of IgE and induced the speciﬁc
release of the TH2 promoting cytokines IL-4 and IL-13, while the
HIV Tat protein induced chemotaxis of mast cells and enhanced
the expression of CCR3 (Marone et al., 2001a). The latter serves as
a receptor for viral entry. Based on this it was proposed that mast
cells can also promote viral infection by serving as a reservoir for
HIV. However, recent systematic colocalization studies in HIV-
infected patients did not conﬁrm active viral presence in various
tissue mast cells (Nelson et al., 2009).
PHYSIOLOGICAL ROLES OF MAST CELLS IN INFLAMMATION
MAST CELLS AS CRUCIAL IMMUNOREGULATORS OF TISSUE REPAIR
Besides functioning in host defense mechanisms in the context of
infection, mast cells also participate more generally in the orches-
tration of inﬂammatory responses initiated after tissue injury
(Laffargue et al., 1999; Maurer et al., 2003; Blank et al., 2007), in
response to certainmetabolic conditions (Liu et al., 2009), through
hormonal signals (Matsumoto et al., 2001; Rudolph et al., 2004;
Jensen et al., 2010), during cancer (Theoharides and Conti, 2004;
Metz and Maurer, 2007; Galinsky and Nechushtan, 2008), or by
signals emanating from the nervous system (Mori et al., 2002; Van
Diest et al., 2011). Participation is made possible by the expression
of numerous types of receptors enabling appropriate responses of
mast cells (Table 2). Indeed, after stimulation mast cells directly
evoke a large variety of tissue responses via the release of spe-
ciﬁc inﬂammatory mediators, the best known example of which
being probably the vasodilatory action of released histamine. They
also secrete many products involved in the orchestration of tissue
remodeling including some proteases and cytokines. Many new
studies also highlight their ability to migrate to the inﬂammatory
site where they interact with other tissue resident or inﬁltrating
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cells. They also show their ability to mediate immunoregulatory
functions through the release of cytokines and/or by fostering
the cross-talk with other immune cells through the release of
chemokines or small molecular weight chemotactic compounds
(Metz and Maurer, 2007; Galli et al., 2008b).
Thepresence of immune cells during inﬂammatory responses is
often considered as being causally linked to the disease process. It
has become clear, however, that inﬁltrating cells including mast
cells are also necessary to the resolution of inﬂammation and
maintenance of tissue homeostasis. Although mast cell-deﬁcient
mice do not show grossly disturbed tissue integrity, an impact can
readily be measured upon speciﬁc challenge. It has been shown in
various experimental settings that mast cells can play pivotal roles
in tissue protection and repair (Maurer et al., 2003). Some strik-
ing examples have already been mentioned above showing that
their capacity to rapidly release granule-contained mediators con-
tributes to detoxiﬁcation against potentially dangerous exogenous
or endogenous substances such as venoms or inﬂammatory pep-
tides. They also participate in the prevention of acute and chronic
damage induced by ultraviolet radiation. This involves their abil-
ity to suppress certain immune effector cells via the secretion of
immunoregulatory cytokines such as IL-10 (see below). A physio-
logical role of mast cells was also demonstrated both in in vitro
and in in vivo models of wound healing (Weller et al., 2006).
Wound healing is a complex event that involves interactions of
various cell types, such as lymphocytes,monocytes, epithelial cells,
and ﬁbroblasts. Mast cells inﬂuence the wound healing process by
increasing ﬁbroblast migration and proliferation (Levi-Schaffer
and Kupietzky, 1990), an effect partially mediated by histamine,
IL-4 and tryptase (Pombo et al., 2001; Levi-Schaffer and Pilipon-
sky, 2003). In addition, mast cells also recruit other inﬂammatory
cells engaged in the wound healing process via the secretion of
various chemokines.
PROTECTIVE FUNCTIONS OF MAST CELLS IN KIDNEY DISEASE
Recently, a protective function of mast cells was reported in kid-
ney disease. It was known for quite some time that mast cell
numbers increase during various types of inﬂammatory CKD.
Although this was usually interpreted as a disease contributing
factor several recent studies support a more subtle view. Two stud-
ies conducted inW/Wv mice reported thatmast cells are protective
in an experimental model of glomerulonephritis induced by the
injection of antibodies against the glomerular basement mem-
brane (GBM; Hochegger et al., 2005; Kanamaru et al., 2006). The
ﬁrst study attributed the protective action of mast cells to their
ability to initiate remodeling responses limiting the deposition of
pathologic ﬁbrin and collagen within glomeruli. In agreement,
mast cell-deﬁcient mice were unable to maintain high levels of
tPA and uPA activity found in urine during the healing process.
The second study rather supported an immunoregulatory role
of mast cells, which dampens inﬂammatory cell inﬁltration and
the inﬂammatory process. Interestingly, a third study, despite
being conducted in the same background of W/Wv mice, reached
the opposite conclusion supporting a disease-aggravating role of
mast cells by increasing inﬂammatory TH1 responses through the
upregulation of adhesion molecules, which promotes inﬂamma-
tory cell inﬁltration (Timoshanko et al., 2006). Although the three
studies lead to different conclusions, these differences may again
reveal the importance of the pathophysiological context leading
to contrasting functions of the MC as an effector of inﬂamma-
tion. Thus, we postulated that the mast cell-dependent action
in glomerulonephritis relies on the speed of disease develop-
ment (Blank et al., 2007; Tiwari et al., 2008). While the ﬁrst two
studies employed an acceleratedmodel of anti-GBMnephritis pro-
moting the surveillance function of mast cells, the third study
used a non-accelerated model allowing mast cells to support a
TH1-directed immune response that promoted injury. The com-
plexity is even further illustrated by follow-up studies showing
that in the accelerated model, while the overall action of mast
cells was found to be protective, examination of the role of a par-
ticular mast cell mediator, the mMCP-4 chymase, was found to
be disease-promoting, notably by supporting an inﬂammatory
response, likely sparked by the ability of mMCP-4 to produce
increased amounts of nephrotoxic angiotensin II (Scandiuzzi et al.,
2010).
ROLE OF MAST CELLS IN SKIN HOMEOSTASIS
Mast cells are highly predominant in the skin, where they play
an important roles in maintaining skin homeostasis. Although
mast cells can participate as effector cells in contact hypersensi-
tivity reaction to irritants (Mackenzie et al., 1981; Nakae et al.,
2005), rather surprisingly, new results show that mast cells in the
long-term instead of promoting inﬂammatory skin reactions can
also limit their magnitude and duration in some experimental
set-ups and thus contribute to the maintenance of homeostasis
(Grimbaldeston et al., 2007). This was shown in two examples of
adaptive immune responses of contact hypersensitivity to urushiol
or dinitroﬂuorobenzene (DNFB) and in innate response to chronic
low-dose UVB irradiation. Indeed,while after primary immuniza-
tion no differences were observed after rechallenge (up to 48 hrs)
between WT and mast cell-deﬁcient mice (Wsh and W/Wv), the
latter became much more susceptible after longer time periods.
In all disease models protection could be restored after reconsti-
tution with cultured WT mast cells, but not IL-10-deﬁcient mast
cells suggesting that local production of immunosuppressive IL-10
by mast cells limits the extent of pro-inﬂammatory cell inﬁltrate
into the skin. Additional studies indicated a possible implication
of Fc receptors, likely FcγRIII, in the adaptive model, as reconsti-
tution with FcRγ-deﬁcient mast cells was less efﬁcient to restore
protection. By contrast, in the innate UVB-induced model they
were equally effective as WT cells. Given that FcR-mediated stim-
ulation also induces release of disease-promoting mediators such
as TNF-α (Nakae et al., 2005), the exact mechanism still needs to
be further deﬁned, but could depend on the timing of stimula-
tion as well as additional cofactors. In the UVB-induced model,
evidence was presented that UV-generated Vitamin D3 activates
mast cells via its nuclear receptor VDR to induce IL-10 produc-
tion in the absence of degranulation, which in consequence cur-
tails pro-inﬂammatorymediator production (particularly TNF-α)
and immune cell inﬁltration (Biggs et al., 2010). While these
data show the ability of mast cells to limit inﬂammation, other
products have been shown to rather enhance contact hypersensi-
tivity responses. This includes for example the hapten oxazalone
which, via an IgE/FcεRI mediated axis, promotes CHS responses
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(Bryce et al., 2004). However, new studies again indicate that this
pro-inﬂammatory action can be shifted to an anti-inﬂammatory
action under speciﬁc circumstances. Thus,while CHS elicitedwith
low-dose oxazalone led to a mast cell mediated CHS, elicitation
with high dose oxazolone promoted an immunosuppressive action
of mast cells that was able to limit the ensuing T cell response
(Kobayashi et al., 2010). Similar immunosuppressive actions have
also been reported in a model of experimental malaria induced
by bites of Anopheles stephensi, where mast cells where shown to
suppress the development of an adaptive T cell response. This was
associated with increased IL-10 levels in draining lymph nodes
(Depinay et al., 2006). Similarly,mast cells by their ability to inter-
act with regulatory T cells can promote allograft tolerance, an
effect that was shown to require IL-9 produced by regulatory T
cells (Lu et al., 2006). Interestingly, regulatory T cells have also
been shown to limit mast cell degranulation and allergic-type
reaction, an effect that involved direct cell–cell interaction medi-
ated via OX40–OX40L (Gri et al., 2008) further indicating that an
intense cross-talk between inﬂammatory effector cells is operant
in tissues. Taken together, these data and those described above
on kidney disease favor a scenario whereby under strong stimu-
latory conditions (accelerated glomerulonephritis model, strong
irritants) or chronic stimulation (chronic UVB), mast cells act as
sensors that initiate an appropriate repair response and/or initiate
immunoregulatory functions in order to prevent further damage.
Under low or moderate stimulatory conditions (non-accelerated
glomerulonephritis model, low-dose irritant), they rather shift the
balance to a pro-inﬂammatory action in order to ﬁght the mecha-
nisms leading to injury (Figure 2). Thus, besides their role in bona
ﬁde immune defense mechanisms mast cells may have evolved
as regulatory cellular sensors that, depending on the particular
circumstances, can limit further damage caused by an exagger-
ated inﬂammatory response or boost inﬂammatory responses
when they are insufﬁciently robust. This opens the possibility
that these opposite functions could also be timely activated in
the course of an inﬂammatory reaction with ampliﬁcation as the
main early function and dampening as the main late function
of mast cells, thus favoring a smooth resolution of the insulting
damage.
PATHOLOGICAL ROLE OF MAST CELLS IN INFLAMMATORY
DISEASES
Although the idea of a sensor function for the strength of an
inﬂammatory response likely serves to reduce pathological con-
sequences, the danger remains that its dysregulation promotes
inﬂammatory diseases. Such dysregulation may be the result of
chronic stimulation or the consequence of an inadequate regu-
latory process (Nathan, 2002). Thus, in addition to their well-
recognized role in IgE-mediated allergic diseases, evidence has
emerged pointing to the involvement of mast cells in a variety
of human inﬂammatory diseases such as RA, multiple sclerosis,
ﬁbrosis, and even cancer (Theoharides et al., 2010). Based on their
wide tissue distribution, their ability to increase in number after
inﬂammation or to release mediators that act locally and system-
ically, mast cells could play a role in virtually every tissue and
inﬂammatory disease process. Therefore, over the last 15 years our
view has rapidly expanded to suggest that mast cells are integral
FIGURE 2 | Mast cells function as cellular sensors. Mast cells are
components of the innate and adaptive immune surveillance system in
tissues. Following an injurious event, mast cells become activated and
release a whole array of pro-inﬂammatory mediators. Their activation will
promote a tissue inﬂammatory response characterized by the cellular
cross-talk with tissue resident cells and other tissue inﬁltrating cells
through released products or direct cell–cell contact. Mast cell activation is
controlled by multiple additional factors that highly depend on a given
genetic background and the local environment. Studies in recent years have
revealed that mast cells are able to differentially control this response by
initiating either a pro- or anti-inﬂammatory program destined for tissue
repair and conditioned by the nature of the initial injurious event (strength,
type, etc., for explanation see text). Mast cells can therefore be viewed as
cellular sensors that direct tissue responses in inﬂammation and immunity
as a function of the stimulus and physiological/pathological context.
Dysregulation of this sensor function by chronic stimulation or defective
control mechanisms can promote pathology and lead to inﬂammatory and
auto-immune diseases.
players of the inﬂammatory process and can contribute to a wide
range of pathologies.
MAST CELLS AS ESSENTIAL PLAYERS IN THE LONG-TERM
CONSEQUENCES OF ASTHMA
Besides their role in the initiation of allergic disease and allergic
asthma recent research has clearly unveiled thatmast cells also con-
tribute to the progression of such diseases. Their participationmay
involve multiple features, which again may be largely driven by the
pathophysiological context. Allergic asthma, a chronic inﬂamma-
tory disease is characterized by airway inﬂammation, bronchial
hyperreactivity, and airway obstruction. In humans, strong evi-
dences exist indicating that mast cells participate in all of these
responses (Bradding et al., 2006). Thus, via IgE-dependent degran-
ulation, synthesis of lipid compound and cytokine/chemokine
production mast cells can promote the onset of an inﬂammatory
response favoring the inﬂux of other cell types such as T cells and
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eosinophils (Galli et al., 2008b). Mast cell derived mediators such
as histamine also favormucus production by goblets cells (Shimizu
et al., 2003). While mucus production is initially intended to
protect lung epithelium from harmful substances, it will promote
airway obstruction in case of chronicity. Mast cells also contribute
to smooth muscle contractions either directly via prostaglandins
and leukotrienes or via the transformation of smooth muscle cells
into a more contractile phenotype via tryptase-dependent upreg-
ulation of TGFβ (Tatler et al., 2008).While these features have been
evaluated inhumans and are alreadypart of asthma therapies,mast
cell participation in experimental animal model has not become
obvious in all models. Thus, models which employ immunization
protocols with alumwhich strongly activate theNALP3 inﬂamma-
somewere found to bemast cell independent,while immunization
with antigen in the absence of adjuvant clearly reveals the implica-
tion of mast cells (Williams and Galli, 2000). In addition, asthma
has been described as a chronic disease involving an ampliﬁca-
tion loop based on excessive tissue remodeling which ﬁnally leads
to tissue destruction (Holgate, 2010) that cannot easily be trans-
ferred to experimental murine models. However, establishment of
a long-term protocol enabled to show, at least in part, that mast
cells participate in key features of chronic asthma such as the ini-
tiation and maintenance of an inﬂammatory cell inﬁltrate, goblet
cell hyperplasia and collagen deposition (Yu et al., 2006). Inter-
estingly, reconstitution experiments using WT and FcRγ-deﬁcient
mast cells showed that many aspects only partially involved an
IgE or IgG-dependent process and show that mast cells also par-
ticipated via FcR-independent activating mechanisms. Again, the
situation may be complex as some of the mediators produced by
mast cells were shown to have opposite protective effects. Thus, in
a mouse model of allergic asthma in mice deﬁcient for the mast
cell chymase mMCP-4 airway hyperresponsiveness and lung air-
way inﬂammation was signiﬁcantly increased. This was correlated
with an increased thickening of the smooth muscle cell layer indi-
cating that this mMCP-4 chymase could regulate smooth muscle
cell activity (Waern et al., 2009).
ROLE OF MAST CELLS IN INFLAMMATORY SKIN DISEASES
Mast cells are also implicated in skin diseases such as chronic
urticaria, atopic dermatitis, contact hypersensitivity and psoriasis
(Navi et al., 2007; Harvima et al., 2008; Kaplan and Greaves, 2009;
Kawakami et al., 2009; Liu et al., 2011). Although these diseases are
complex and involve multiple etiologic factors, there is evidence
that mast cells participate in multiple features of disease devel-
opment. Generally, these diseases have in common an increase of
either mast cells or mast cell-derived mediators in the skin (Navi
et al., 2007). Mast cells may therefore contribute to disease devel-
opment either directly or indirectly via the production of speciﬁc
mediators. For example,mast cell-released histamine plays amajor
role in the generation of skin rash, wheals, and hives that become
apparent in urticaria (Mlynek et al., 2008). In contact hypersen-
sitivity, mast cell-produced TNF may play a role in the initiation
and translation of the T cell mediated delayed type hypersensi-
tivity responses (Nakae et al., 2005). In atopic dermatitis, mast
cells contribute to disease development by the generation of pru-
ritus symptoms through release of histamine and tryptase (Ikoma
et al., 2003; Steinhoff et al., 2003). Mast cells were also shown to
become activated by thymic stromal lymphopoietin (TSLP) that
is produced in high amounts by keratinocytes in AD skin lesions
(Yoo et al., 2005; Allakhverdi et al., 2007). TSLP stimulation pro-
motes the release of TH2 cytokines involved in the development of
atopic dermatitis (He andGeha, 2010). In psoriasis, in early lesions
inﬁltrated mast cells show a degranulated phenotype and contain
at high frequencies IFN-γ (Harvima et al., 2008), while in AD
the majority stains positive for IL-4 suggesting that mast cells via
differential cytokine production inﬂuence immune response para-
meters (Horsmanheimo et al., 1994). A common feature of these
diseases is also the involvement of emotional stress. It has been
known that mast cells can often be found in close functional and
anatomical association with sensory nerves in the skin (Arck et al.,
2006; Harvima et al., 2010). During emotional stress, mast cells
can therefore function as neuroinﬂammatory sensors that become
activated through peptides and hormones released by the neu-
roendocrine system and peripheral sensory nerves, which release
neuropeptides, neurotrophins, corticotropin-releasing hormone
and α-melanocyte-stimulating hormone, which are capable of
activating mast cells (Arck et al., 2006; Theoharides et al., 2010).
Inversely, mast cell-derived mediators (histamine, tryptase) can in
turn excite and stimulate surrounding neuropeptide-containing
C-ﬁbers possibly resulting in an ampliﬁcation loop of neuro-
genic inﬂammation (Harvima et al., 2010). However, as stated
above, mast cells, when present in chronic lesions, may also have
immunosuppressive functions via the production of the immuno-
suppressive cytokine IL-10 in order to limit disease. In this context
it may be interesting to note that psoriasis lesions are treated
with Vitamin D analogs and that Vitamin D has been shown to
selectively induce the production of IL-10 by mast cells.
MAST CELLS AND GASTROINTESTINAL DISEASE
Mast cells are also found in large numbers in the gastrointesti-
nal (GI) tract, where they may play an important function in
the regulation of GI barrier functions (Bischoff, 2009). Given its
large contact surfaces with the external environment and colo-
nization with billions of microbes the GI barrier comprises mul-
tiple defense mechanisms which maintain integrity. This includes
epithelial cell functions (mucus production, secretory functions,
defensin release, etc.), regulation by innate and adaptive immune
cells and the enteric nervous system (Bischoff, 2009). Dysregu-
lation or breakdown of a single system results in disease. For
example, impairment of defensin production has been associated
with inﬂammatory bowel disease and ulcerative colitis (Wehkamp
et al., 2009). Mast cells can interact in multiple ways with systems
of the GI barrier. Release of mast cell mediators, such as hista-
mine, can directly increase mucosal permeability and, as seen in
the lung, increase mucus production (Bischoff, 2009). We have
already seen above that mucus production plays an important role
in the expulsion of intestinal parasites. Mast cell mediators also
directly inﬂuence epithelial cell secretion. Evidence comes from
studies in systemic mastocytosis patients where 70–80% of the
patients report GI symptoms including diarrhea (Jensen, 2000). In
pathophysiology, diarrhea is part of the mucosal defense system
against microbes, parasites, toxins, or other harmful substances.
Mast cells via release of multiple cytokines and chemokines
are also known to regulate in multiple ways innate or adaptive
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immune effector cells, for example by promoting their activi-
ties, proliferation or by initiating their recruitment. Part of the
GI tract-mediating actions may also be related to the capacity of
mast cells to respond to signals of the enteric nervous system.
Based on these multiple functions it is clear that chronic stim-
ulation or dysregulation of mast cells can be associated with GI
disease such as seen in the case of food allergies (Brandtzaeg,
2002). Apart from their role in allergies mast cells have been
suggested to be involved in other pathologies of the GI tract.
In celiac disease patients, local challenge with gliadin led to a
decrease in mast cell numbers and histamine with a concomi-
tant increase in CD4 T lymphocytes number (Lahteenoja et al.,
2000). The decrease in mast cell numbers is likely the result of IgE-
independent degranulation diminishing the number of countable
mast cells with granule-staining methods. Similarly, in inﬂam-
matory bowel syndrome, although no differences in mast cell
numbers were found, speciﬁc analysis of locally inﬂamed tis-
sue showed an apparent decrease in their numbers, again likely
due to degranulation (Bischoff et al., 1996), which suggests that
in affected areas mast cells are activated. By contrast, patients
with irritable inﬂammatory bowel syndrome, an affection with
still unknown origins characterized by low grade inﬂammation,
show mast cell hyperplasia (De Giorgio and Barbara, 2008). They
may become activated under certain conditions and this could be
directly related to the generation of symptoms by their bioactive
mediators. At present, the precise triggers of mast cell activation
(except for allergies) in these manifestations remain unknown.
Animal models for these complex GI diseases are also missing,
which may at least in part depend on altered microbial colo-
nization of the human gut and thus could depend on certain
microbial gene products that yet need to be identiﬁed (Qin et al.,
2010).
THERAPEUTIC APPLICATIONS
Development of therapies relating to mast cell functions was
initially largely driven by their role they play in allergies. They
were aimed to limit the effects of mast cell mediators, in par-
ticular histamine, leading to the generation of new classes of
anti-histamineswith less sedating side-effects (Banerji et al., 2007),
anti-leukotrienes (Calhoun, 2001), but included also the develop-
ment of mast cell stabilizers (Gebbie et al., 1972). More recently,
this has also led to the development of humanized anti-IgE anti-
bodies (Omalizumab), although such treatment stays reserved for
severe cases of allergies and asthma that are uncontrollable with
corticosteroids due to its costs (Busse, 2001). However, the recent
data of the broad inﬂuence of MCs and their many products in
exacerbating inﬂammatory disorders, call for further research to
limit mast cell activity and suggest that certain drugs may also be
applicable for other types of applications. In this respect, tyrosine
kinase inhibitors targeting the mast cell growth factor receptor c-
kit such asmasitinib and imatinib have shown promising results in
several inﬂammatory diseases as well as in certain cancers (Eklund
and Joensuu, 2003; Dubreuil et al., 2009; Humbert et al., 2009).
On the other hand, mast cells have also been shown to exhibit
many beneﬁcial actions suggesting that development of drugs
enhancing mast cell functions may also be useful in certain disease
set-ups, although care has to be taken with regard to the potential
side-effects of anaphylactic type of reactions, as for example noted
in the treatment with omalizumab (Busse, 2001).
CONCLUDING REMARKS
Mast cell or mast cell like cells have emerged early in evolution
appearing already in primitive organisms like tunicates (Caval-
cante et al., 2000) before other classical immune effector cells
like neutrophils, monocytes, and lymphocytes (Rowley, 1996).
They may be part of an ancient defense system that protected tis-
sues against foreign invaders or harmful substances and that have
been maintained during evolution acquiring additional proper-
ties, enzymes, and mediators to fulﬁll these functions, eventually
in concert with other immune effector cells. As evidenced by the
multiple examples described in this review they continue to play
an important role in a number of defense and repair mechanisms
due to their strategic location in tissues at the interface with the
environment. Within the vertebrate immune system mast cells
are, together with basophils, the prime mediators of IgE-mediated
hypersensitivity responses that probably have co-evolved together
with a need for defense against parasitic infections. We have also
seen that their inappropriate activation can result in inﬂammatory
and auto-immune disease where mast cells can be either prime
effectors, such as for example in allergic diseases, or participating
actors. New data also show that their degree of participation in
physiology and pathology very much depends on a given patho-
physiological context. Thus, genetic factors, the local microenvi-
ronment, the presence, and interaction with other immune cells or
tissue resident cells are important and can interfere with or over-
take certain functions. This explains some differences which have
been observed in various experimental mouse models of disease.
Mast cells also release a whole array of inﬂammatory products
some of which may act in an opposite manner when compared
to the general action of mast cells in a particular pathological
disease model. This illustrates the complexity of an inﬂamma-
tory response, which is composed of pro-inﬂammatory but also
regulatory anti-inﬂammatory components. The action of media-
tors also strongly depends on the disease context. Some mediators
like TNF-α may have a prime protective function in host defense
mechanisms against bacteria but can also signiﬁcantly contribute
to pathogenesis of skin diseases.Most intriguingly, these new stud-
ies have made clear that mast cells can initiate a whole spectrum
of responses and thus that they act as sensors of their tissue envi-
ronment to undertake appropriate actions. Thus, while one would
think that mast cells engage an inﬂammatory response to restore
homeostasis, several studies now also show that they can also limit
inﬂammation by the promotion of immunosuppressive functions,
likely to limit the negative side-effects of an inﬂammatory over-
shot. These two-face functions unveil mast cells as important
microenvironment sensors involved in the maintenance of tissue
homeostasis.
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